Findings

What do systematic reviews say?

4 questions · 5 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 5 · 100%High 0 · 0%

Recurrence · adults with basal cell carcinoma of the skin

Imiquimod cream probably leads to lower recurrence at 3 years compared with MAL‐PDT (moderate certainty).

2 findings from 1 review

Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
RR 0.44 [0.32, 0.62]
1 study · 277 participants
Moderate
Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
RR 0.42 [0.31, 0.57]
1 study · 228 participants
Moderate

Cosmesis · adults with basal cell carcinoma of the skin

Imiquimod cream showed no clear difference in cosmetic outcome (excellent/good) compared with MAL‐PDT (moderate certainty).

1 finding from 1 review

Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
RR 0.98 [0.84, 1.16]
1 study · 370 participants
Moderate

Number of patients with moderate/severe pain (1 hour postoperatively) · adults with basal cell carcinoma of the skin

Imiquimod cream probably leads to lower pain (moderate/severe) compared with MAL‐PDT (moderate certainty).

1 finding from 1 review

Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
RR 0.6 [0.41, 0.87]
1 study · 371 participants
Moderate

Early treatment failure · adults with basal cell carcinoma of the skin

Imiquimod cream showed no clear difference in early treatment failure compared with MAL‐PDT (moderate certainty).

1 finding from 1 review

Interventions for basal cell carcinoma of the skin 2020 · Cochrane Headline outcomes only
RR 0.64 [0.37, 1.09]
1 study · 385 participants
Moderate